F-star, an invoX company
BiotechnologyView the employees at
F-star, an invoX company-
Emma McConnell Manager, In Vivo Biology at F-star Therapeutics, Inc.
-
Letchworth, England, United Kingdom
-
Rising Star
Jennifer Parsons Director, Finance at F-star Therapeutics, Inc.-
Rising Star
Mateusz Wydro VP, CMC at F-star Therapeutics, Inc.-
Rising Star
-
Greater Boston
-
Top 10%
Wolfgang Koch Principal Scientist at F-Star Therapeutics Inc.-
Greater Cambridge Area
-
Top 5%
Overview
F-star, an invoX company, is a clinical-stage biopharmaceutical business pioneering bispecific antibodies in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. F-star has four second-generation immunooncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate, with over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several areas, including oncology, immunology, and CNS.
-